Showing results (631-640 of 977) with videos related to
Sort By:
Pageof 98
NPJ Breast Cancer|May 11, 2026
Prediction of OncotypeDX recurrence score using hematoxylin and eosin-stained whole slide imagesShachar Cohen, Gil Shamai, Edmond Sabo, et al.NPJ Breast Cancer|May 15, 2026
Expert recommendations for PIK3CA testing in HR+/HER2- locally advanced and metastatic breast cancerCaterina Marchiò, Federico Rojo, Ellen R Copson, et al.NPJ Breast Cancer|May 12, 2026
Clinical significance of residual microcalcifications after neoadjuvant chemotherapy: MRI response and the subtypesSoong June Bae, Seung Ho Baek, Yoonwon Kook, et al.NPJ Breast Cancer|March 13, 2026
The landscape of B and plasma cells in breast cancer: insights from single-cell and spatial transcriptomicsXing Cai, Jinru Yang, Wenzheng Wang, et al.NPJ Breast Cancer|February 21, 2026
Trimester of diagnosis affects tumor characteristics and survival in breast cancer during pregnancy: first results from the STURGATE collaborationCarsten F J Bakhuis, Leo Gkekos, Paul J van Diest, et al.NPJ Breast Cancer|February 20, 2026
Clinical and histopathological characterization of metastatic lobular breast cancer: lessons learned from post-mortem tissue donation programsGitte Zels, Karen Van Baelen, Alexander Cc Chang, et al.NPJ Breast Cancer|November 21, 2018
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancerCharles E Geyer, Gong Tang, Eleftherios P Mamounas, et al.NPJ Breast Cancer|March 2, 2019
ESR1 mutations in metastatic lobular breast cancer patientsChristine Desmedt, Julien Pingitore, Françoise Rothé, et al.NPJ Breast Cancer|April 18, 2023
Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumoursJian Zhang, Rujiao Liu, Shuiping Gao, et al.NPJ Breast Cancer|February 12, 2026
JAK/STAT1-interferon-ISGylation networks in breast cancer resistance to inhibitors of FOXM1 and CDK4/6Yvonne Ziegler, Sandeep Kumar, Carlos M Saeh, et al.Pageof 98